Anthracite Investment Company Inc. Grows Position in Grifols, S.A. (NASDAQ:GRFS)

Anthracite Investment Company Inc. boosted its position in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 659,964 shares of the biotechnology company's stock after acquiring an additional 45,410 shares during the quarter. Grifols accounts for approximately 1.7% of Anthracite Investment Company Inc.'s portfolio, making the stock its 11th largest holding. Anthracite Investment Company Inc. owned about 0.10% of Grifols worth $4,910,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in GRFS. JPMorgan Chase & Co. lifted its position in Grifols by 144.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after buying an additional 1,181,959 shares during the last quarter. Helikon Investments Ltd purchased a new stake in shares of Grifols in the 4th quarter valued at $580,000. Stifel Financial Corp purchased a new position in Grifols in the 3rd quarter worth $1,043,000. GAMMA Investing LLC lifted its stake in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 1,527 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Grifols during the third quarter valued at about $363,000.

Grifols Trading Down 0.5 %

Grifols stock traded down $0.04 during trading hours on Friday, reaching $7.27. The stock had a trading volume of 586,558 shares, compared to its average volume of 1,231,491. The company has a fifty day simple moving average of $7.56 and a 200-day simple moving average of $8.05. The stock has a market cap of $5.00 billion, a PE ratio of 6.21 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on Grifols in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.